POPULARITY
Drs Carol H. Wysham and Liana K. Billings discuss how to incorporate SGLT2 inhibitors and GLP-1 receptor agonists into the management of patients with type 2 diabetes and chronic kidney disease. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002049. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Type 2 Diabetes Mellitus https://emedicine.medscape.com/article/117853-overview Chronic Kidney Disease (CKD) https://emedicine.medscape.com/article/238798-overview Global, Regional, and National Burden of Chronic Kidney Disease Due to Diabetes Mellitus Type 2 From 1990 to 2021, With Projections to 2036: A Systematic Analysis for the Global Burden of Disease Study 2021 https://pubmed.ncbi.nlm.nih.gov/40034386/ Advantages, Limitations, and Clinical Considerations in Using Cystatin C to Estimate GFR https://pubmed.ncbi.nlm.nih.gov/36514729/ New Creatinine- and Cystatin C-Based Equations to Estimate GFR Without Race https://pubmed.ncbi.nlm.nih.gov/34554658/ Effects of Semaglutide on Chronic Kidney Disease in Patients With Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/38785209/ Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy https://pubmed.ncbi.nlm.nih.gov/30990260/ Dapagliflozin in Patients With Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/32970396/ Empagliflozin in Patients With Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/36331190/ Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 https://pubmed.ncbi.nlm.nih.gov/39651975/ CKD Early Identification & Intervention Toolkit https://kdigo.org/wp-content/uploads/2019/01/ISN_KDIGO_EarlyScreeningBooklet_WEB_updatedOct11.pdf Combination Therapy as a New Standard of Care in Diabetic and Non-Diabetic Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/39907542/ Living With Chronic Kidney Disease and Type 2 Diabetes Mellitus: The Patient and Clinician Perspective https://pubmed.ncbi.nlm.nih.gov/36282450/
In this episode, Martina McGrath, MD, FASN, talks with guest editors Laurence H. Beck, Jr., MD, PhD, and Joyita Bharati, MD, about their editorial "A Renaissance of Clinical Trials for IgA Nephropathy" from nephSAP, Vol. 24, No.1 on glomerular diseases.
In this episode, Martina McGrath, MD, FASN, talks with guest editors Laurence H. Beck, Jr., MD, PhD, and Joyita Bharati, MD, about their editorial "A Renaissance of Clinical Trials for IgA Nephropathy" from nephSAP, Vol. 24, No.1 on glomerular diseases.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/XJK865. CME credit will be available until February 25, 2026.Advancements in IgA Nephropathy: Discovering the Potential of Complement Pathway TherapiesPurdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This accredited activity has been developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/XJK865. CME credit will be available until February 25, 2026.Advancements in IgA Nephropathy: Discovering the Potential of Complement Pathway TherapiesPurdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This accredited activity has been developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/XJK865. CME credit will be available until February 25, 2026.Advancements in IgA Nephropathy: Discovering the Potential of Complement Pathway TherapiesPurdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This accredited activity has been developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/XJK865. CME credit will be available until February 25, 2026.Advancements in IgA Nephropathy: Discovering the Potential of Complement Pathway TherapiesPurdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This accredited activity has been developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/XJK865. CME credit will be available until February 25, 2026.Advancements in IgA Nephropathy: Discovering the Potential of Complement Pathway TherapiesPurdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This accredited activity has been developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/XJK865. CME credit will be available until February 25, 2026.Advancements in IgA Nephropathy: Discovering the Potential of Complement Pathway TherapiesPurdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This accredited activity has been developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
Sanjeev Sethi, M.D., Ph.D., explains how Mayo Clinic Laboratories' new mass spectrometry test (Mayo ID: MSMN) identifies most antigens now known to cause membranous nephropathy. Precise identification of antigens is important for optimal management of this serious kidney disease.Speaker 3: (00:32) Would you mind telling us a little bit about yourself and your background? Speaker 3: (01:58) Would you give us an overview of membranous nephropathy? Speaker 3: (07:14) Could you tell us a little bit about this new assay? Speaker 3: (14:29) Could you give a little example of how a clinician might use this information to treat their patients differently than how they would've in the past?
Our experts will take you through patient cases and the latest clinical data for potentially game-changing therapies for patients with IgA nephropathy (IgAN). Credit available for this activity expires: 01/03/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/emerging-iga-nephropathy-advances-digging-deep-b-cell-2024a1000pfe?ecd=bdc_podcast_libsyn_mscpedu
Please visit answersincme.com/NRR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in the treatment of IgA nephropathy (IgAN) discusses novel therapeutic approaches in the management of IgAN. Upon completion of this activity, participants should be better able to: Outline the unmet needs in patients with IgAN; Discuss the clinical implications of new and emerging targeted therapies in IgAN; and Identify patient-centered strategies for long-term management of IgAN.
Dana Rizk, MD - Unlocking the Potential of B-Cell Modulation Therapies in IgA Nephropathy
Dana Rizk, MD - Unlocking the Potential of B-Cell Modulation Therapies in IgA Nephropathy
Beyond the Pearls: Cases for Med School, Residency and Beyond (An InsideTheBoards Podcast)
Today's Episode Charlee reviews chapter 23 from the Pediatric Morning Report book. A 10-year-old female presents to clinic reporting recurrent episodes of burning pain during urina- tion, urinary incontinence, and increased urinary frequency. She has a history of recurrent urinary tract infections (UTIs). The present urinary symptoms started 2 days ago. She denies having fever, chills, nausea, vomiting, abdominal pain, or flank pain. In between these episodes, the child denies having urinary urgency, hesitancy, and incontinence. She has one bowel movement per day and reports no history of constipation. Today's Host Charlee Quarless is a 3rd year medical student at Ross University. About Dr. Raj Dr Raj is a quadruple board certified physician and associate professor at the University of Southern California. He was a co-host on the TNT series Chasing the Cure with Ann Curry, a regular on the TV Show The Doctors for the past 7 seasons and has a weekly medical segment on ABC news Los Angeles. More from Dr. Raj www.BeyondThePearls.net The Dr. Raj Podcast Dr. Raj on Twitter Dr. Raj on Instagram Want more board review content? USMLE Step 1 Ad-Free Bundle Crush Step 1 Step 2 Secrets Beyond the Pearls The Dr. Raj Podcast Beyond the Pearls Premium USMLE Step 3 Review MedPrepTGo Step 1 Questions Learn more about your ad choices. Visit megaphone.fm/adchoices
A macrovascular complication of diabetes, diabetic nephropathy is progressive, chronic kidney disease seen in patients with both type 1 and type 2 diabetes mellitus, usually after at least 10 years of hyperglycemia (high blood glucose levels). The three main lesions that are seen in the kidney in patients with diabetes are glomerular lesions, vascular lesions, and pyelonephritis. This brick will focus primarily on the first two of these three lesions; diabetic pyelonephritis is covered in a separate brick. After listening to this AudioBrick, you should be able to: Define diabetic nephropathy. Outline the timeline of progression of diabetic nephropathy (DN) by urine, serum, and histologic criteria. Describe the diagnosis of diabetic nephropathy. Outline the prevention of diabetic nephropathy and, once it is established, how to slow its progression. Describe the management of diabetic nephropathy. You can also check out the original brick from our Renal collection, which is available for free. Learn more about Rx Bricks by signing up for a free USMLE-Rx account: www.usmle-rx.com You will get 5 days of full access to our Rx360+ program, including nearly 800 Rx Bricks. After the 5-day period, you will still be able to access over 150 free bricks, including the entire collections for General Microbiology and Cellular and Molecular Biology. *** If you enjoyed this episode, we'd love for you to leave a review on Apple Podcasts. It helps with our visibility, and the more med students (or future med students) listen to the podcast, the more we can provide to the future physicians of the world. Follow USMLE-Rx at: Facebook: www.facebook.com/usmlerx Blog: www.firstaidteam.com Twitter: https://twitter.com/firstaidteam Instagram: https://www.instagram.com/firstaidteam/ YouTube: www.youtube.com/USMLERX Learn how you can access over 150 of our bricks for FREE: https://usmlerx.wpengine.com/free-bricks/
Richard Lafayette, MD, FACP - Novel Therapies in Focus: Updates in IgA Nephropathy
Richard Lafayette, MD, FACP - Novel Therapies in Focus: Updates in IgA Nephropathy
Novel therapies for IgA nephropathy are discussed in this ASN Kidney Translation podcast episode, including efficacy and safety of ravulizumab, selective endothelin receptor antagonist SC0062, and long-term results from a study of atacicept as treatment.
Jonathan Barratt, PhD, FRCP - Redefining Hope: The IgA Nephropathy Journey
Jonathan Barratt, PhD, FRCP - Redefining Hope: The IgA Nephropathy Journey
Jonathan Barratt, PhD, FRCP - Redefining Hope: The IgA Nephropathy Journey
Jonathan Barratt, PhD, FRCP - Redefining Hope: The IgA Nephropathy Journey
Watch this episode to find out how Ira Sahay, meat eater turned vegetarian turned carnivore reversed her autoimmune condition called membranous nephropathy and other accompanying issues. She now coaches patients with autoimmune issues to reverse syndromes their doctors cannot reverse on medications through lifestyle and nutrition interventions. Catch her on X - @theirasahay IG - @ira_sahay
IgA nephropathy, also known as Berger's disease. It's a kidney disease that can affect people without them even realizing it. We'll explain what IgA nephropathy is, what causes it, its symptoms, and how it's treated in simple, easy-to-understand language. _ The Kidney Zone Podcast with Dr. Mo Welcome to the Kidney Zone, where we will dive deep into the fascinating world of our body's remarkable filters. Get ready to unlock the secrets of the kidneys and transplantation as we travel through their pathways, uncovering vital tips, insightful knowledge, and practical advice to keep our kidneys healthy. Whether you're a patient with kidney disease, a medical professional, or simply curious about the kidneys, this is the place for you. _ Follow Along on Social Media: Facebook: https://www.facebook.com/Dr.Mo.Page Instagram: https://www.instagram.com/dr.mo.ibrahim/ Twitter: https://twitter.com/drmoibrahim TikTok: https://www.tiktok.com/@dr.mo.ibrahim _ Dr. Mo Ibrahim is an assistant professor of kidney transplantation at the University of Maryland, Baltimore. He completed his clinical transplant nephrology fellowship at Washington University in 2022. Originally from Cairo, he pursued a physician/scientist career, conducting research at Duke University from 2012 to 2019. He has authored 70+ journal articles, given a TEDx talk, and holds 5 patents. Currently finishing his PhD at Erasmus University, he drives international collaborations to advance medical technology and improve medical monitoring. _ DISCLAIMER The content of this episode is intended for informational purposes only and is not to be considered medical advice. The information presented here is not meant to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare professional or your doctor before making any healthcare decisions or starting any treatment regimen. Individual medical situations can vary, and only a licensed healthcare provider can offer personalized advice tailored to your specific needs. The creators of this episode are not responsible for any actions taken based on the information provided herein. Any reliance on the content of this episode is at your own risk. If you have any medical concerns or questions, please seek guidance from a medical professional promptly. Remember that medical knowledge and practices can evolve over time, and new information may become available after the creation of this episode. Therefore, it is essential to stay up-to-date with the latest medical research and consult with your healthcare provider to ensure the best possible care for your health.
Listen as Dr. London Smith (.com) and his producer Cameron discuss Sickle Cell Nephropathy with special guest David Copperwater (John Dardenne). Not so boring! https://www.patreon.com/join/jockdocpodcast Hosts: London Smith, Cameron Clark. Guest: John Dardenne. Produced by: Dylan Walker Created by: London Smith
Recent advances in our understanding of immunoglobulin A (IgA) nephropathy (IgAN) have led to an abundance of research into new therapies; our experts will guide you through it all. Credit available for this activity expires: 8/29/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001534?ecd=bdc_podcast_libsyn_mscpedu
Are your patients' kidneys fighting a silent battle? Our experts give insight on earlier detection of IgAN and react to a real patient's experience. Credit available for this activity expires: 8/23/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001513?ecd=bdc_podcast_libsyn_mscpedu
Dive into the fascinating world of immunoglobulin A nephropathy (IgAN), the most common form of primary glomerulonephritis worldwide. Credit available for this activity expires: 7/16/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001351?ecd=bdc_podcast_libsyn_mscpedu
In this CCO Nephrology podcast episode, hear from Kelly Chen, a nephrology nurse practitioner and patient living with IgA nephropathy, as she discusses her experiences with Dr Pietro Canetta, Associate Professor of Medicine at Columbia University and expert in glomerular diseases. Episode outline: Seeking and obtaining an IgAN diagnosis Patient self-advocacy Individualizing IgAN treatment plansClinical trial involvement Burdens of IgAN: physical, emotional, social, and beyondTo learn more about IgA nephropathy, find more educational activities and resources with the links below: CME-certified text module with animated pathophysiology video and patient voice audio clipsClinicalThought commentaries Resources on IgAN from the American Kidney Fund
Listen as Dr. London Smith (.com) and his producer Cameron discuss IgA Nephropathy (Berger Disease) with animal handler Herman Punt (Brennan Lee). Not so boring! https://www.patreon.com/join/jockdocpodcast Hosts: London Smith, Cameron Clark. Guest: Brennan Lee. Produced by: Dylan Walker Created by: London Smith
In this episode of Cardio Buzz, host and guest Dr. Daniel Jones discuss contrast nephropathy, a kidney injury caused by contrast agents used in medical imaging, and a promising intervention to reduce its incidence. Dr. Jones explains that inorganic nitrates, which are naturally found in green leafy vegetables, have shown significant potential in preventing contrast-induced nephropathy and associated acute kidney injuries in a recent study. This study involved 640 high-risk patients and demonstrated that inorganic nitrates reduced kidney injuries by 60% and improved long-term cardiovascular outcomes. The episode concludes with a conversation about the practical implications and future research plans for this intervention.
Dr. Marshall Fordyce, CEO and Founder of Vera Therapeutics, discusses the company's patient-centric approach to developing new medicines for autoimmune diseases. Vera is currently in Phase 3 with a molecule called Atacicept, which targets B cells in autoimmune diseases. They focus on IgA nephropathy, a rare kidney disease, and the third most common cause of kidney failure. A key concern is that declining kidney function is often misdiagnosed and not screened for because the early warning signs are so subtle. Marshall explains, "Let me give you an example of our lead indication. So, our molecule in development is called atacicept. It targets the immune system in the specific area of B cells, and B cells are the factories of our antibodies, which we need to fight infection over our lifetime. But in patients with autoimmune disease, these B cells are overstimulated, they're overactive, and there are only a few medicines that target B cells with an appropriate balance of safety and efficacy. We had an insight that the science told us that by inhibiting two key factors in the body, BAFF and APRIL, we could normalize that overactivity of B cells and have better outcomes." "Now traditional drug development may be long and expensive. We were very strategic in picking IgA nephropathy. This is an area that has had very little drug development over the last decade. A few small companies started to become interested in this area, and thankfully, because of patient advocacy, the FDA allowed a surrogate endpoint in Phase 3 trials, which made it more efficient to bring this molecule forward. So, there are now two drugs on the market for the first time in the last three or four years, for two new drugs in IgA nephropathy. They don't target B cells, which is really what's driving this disease. They work downstream, or they're nonspecific." "What Vera did differently is that we thought that we could actually demonstrate that kidney function, which in these young patients is declining at an alarming rate, if we could demonstrate that kidney function doesn't decline, that would be meaningful. It would be a significant leap. We don't see that happen in "traditional" drug development often, in my view. So, I think what's different here is that we're picking an area where we think we can intervene and, in early-stage development, show a meaningful improvement in outcomes for patients." #VeraTherapeutics #KidneyDisease #RareDisease #BCells #Immunotherapy #AutoimmuneDiseases #IgANephropathy veratx.com Download the transcript here
Dr. Marshall Fordyce, CEO and Founder of Vera Therapeutics, discusses the company's patient-centric approach to developing new medicines for autoimmune diseases. Vera is currently in Phase 3 with a molecule called Atacicept, which targets B cells in autoimmune diseases. They focus on IgA nephropathy, a rare kidney disease, and the third most common cause of kidney failure. A key concern is that declining kidney function is often misdiagnosed and not screened for because the early warning signs are so subtle. Marshall explains, "Let me give you an example of our lead indication. So, our molecule in development is called atacicept. It targets the immune system in the specific area of B cells, and B cells are the factories of our antibodies, which we need to fight infection over our lifetime. But in patients with autoimmune disease, these B cells are overstimulated, they're overactive, and there are only a few medicines that target B cells with an appropriate balance of safety and efficacy. We had an insight that the science told us that by inhibiting two key factors in the body, BAFF and APRIL, we could normalize that overactivity of B cells and have better outcomes." "Now traditional drug development may be long and expensive. We were very strategic in picking IgA nephropathy. This is an area that has had very little drug development over the last decade. A few small companies started to become interested in this area, and thankfully, because of patient advocacy, the FDA allowed a surrogate endpoint in Phase 3 trials, which made it more efficient to bring this molecule forward. So, there are now two drugs on the market for the first time in the last three or four years, for two new drugs in IgA nephropathy. They don't target B cells, which is really what's driving this disease. They work downstream, or they're nonspecific." "What Vera did differently is that we thought that we could actually demonstrate that kidney function, which in these young patients is declining at an alarming rate, if we could demonstrate that kidney function doesn't decline, that would be meaningful. It would be a significant leap. We don't see that happen in "traditional" drug development often, in my view. So, I think what's different here is that we're picking an area where we think we can intervene and, in early-stage development, show a meaningful improvement in outcomes for patients." #VeraTherapeutics #KidneyDisease #RareDisease #BCells #Immunotherapy #AutoimmuneDiseases #IgANephropathy veratx.com Listen to the podcast here
The JournalFeed podcast for the week of April 22-26, 2024.These are summaries from just 2 of the 5 articles we cover every week! For access to more, please visit JournalFeed.org for details about becoming a member.Monday Spoon Feed:In a controlled hypoxemia study, pulse oximetry was falsely elevated in subjects with darker skin pigmentation and low perfusion.Friday Spoon Feed:In patients with ACS and concern for STEMI/NSTEMI requiring urgent intervention, randomization to the contrast volume reduction group reduced the rate of acute kidney injury and sustained kidney damage.
In a Kidney360 article of 31 patients with native kidney biopsy proven oxalate nephropathy, 10 of 31 patients had multifactorial etiologies of oxalate nephropathy. 10 of 31 had a single etiology and 11 had risk factors but the etiology was unknown.
Guest: Jai Radhakrishnan, MD The most widely accepted mechanism for the pathogenesis of immunoglobin A (IgA) nephropathy is referred to as the “four-hit model,” which is a sequence of four events that can occur.1-3 Here to break down each of those four stages is Dr. Jai Radhakrishnan, a nephrologist at Columbia University Medical Center in New York. References: Knoppova B, Reily C, King RG, et al. J Clin Med. 2021;10(19):4501. doi:10.3390/jcm10194501 Maillard N, Wyatt RJ, Julian BA, et al. J Am Soc Nephrol. 2015;26(7):1503-1512. doi:10.1681/ASN.2014101000 Chang S, Li X-K. Front Med (Lausanne). 2020;7:92. doi:10.3389/fmed.2020.00092 319698 12/23
Guest: Richard Lafayette, MD, FACP Insights into the complement system are critical to our understanding of the pathogenesis of immunoglobin A (IgA) nephropathy.1 That's why Dr. Richard Lafayette is here to share what we currently know about the complement system and its role in IgA nephropathy. Dr. Lafayette is a nephrologist at Stanford University Medical Center in California. References: Medjeral-Thomas NR, O'Shaughnessy MM. Adv Chronic Kidney Dis. 2020 Mar;27(2):111-119. doi: 10.1053/j.ackd.2019.12.004 319698 12/23
A new Kidney360 study describes the association between the pre-vaccination microscopic hematuria or proteinuria and post vaccination gross hematuria.
Join experts Drs Matthew Sparks and Laurence Beck as they discuss the diagnosis and management of membranous nephropathy, a rare kidney disease. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/991606). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Chronic Kidney Disease (CKD) https://emedicine.medscape.com/article/238798-overview Membranous Glomerulonephritis https://emedicine.medscape.com/article/239799-overview M-type Phospholipase A2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy https://pubmed.ncbi.nlm.nih.gov/19571279/ The Endocytic Receptor Megalin and Its Associated Proteins in Proximal Tubule Epithelial Cells https://pubmed.ncbi.nlm.nih.gov/25019425/ PLA2R Autoantibodies and PLA2R Glomerular Deposits in Membranous Nephropathy https://pubmed.ncbi.nlm.nih.gov/21323563/ Genome-Wide Association Studies (GWAS) https://www.genome.gov/genetics-glossary/Genome-Wide-Association-Studies Thrombospondin Type-1 Domain-Containing 7A in Idiopathic Membranous Nephropathy https://pubmed.ncbi.nlm.nih.gov/25394321/ New 'Antigens' in Membranous Nephropathy https://pubmed.ncbi.nlm.nih.gov/33380523/ Nephrotic Syndrome https://emedicine.medscape.com/article/244631-overview NAACCR Item #3812: B Symptoms https://staging.seer.cancer.gov/naaccr/item/eod_public/2.1/3812/ Video-Assisted Thoracoscopy https://www.ncbi.nlm.nih.gov/books/NBK532952/ Direct Oral Anticoagulants: A Quick Guide https://pubmed.ncbi.nlm.nih.gov/30416551/ Focal Segmental Glomerulosclerosis https://emedicine.medscape.com/article/245915-overview IgA Nephropathy https://emedicine.medscape.com/article/239927-overview DOAC Compared With Warfarin for VTE in Patients With Obesity: A Retrospective Cohort Study Conducted Through the VENUS Network https://pubmed.ncbi.nlm.nih.gov/36757644/ Is It Lupus Nephritis? A Path to Diagnosis and Treatment https://www.medscape.com/viewarticle/991602 Noninvasive Diagnosis of PLA2R-Associated Membranous Nephropathy: A Validation Study https://pubmed.ncbi.nlm.nih.gov/34782349/ Noninvasive Diagnosis of Primary Membranous Nephropathy Using Phospholipase A2 Receptor Antibodies https://pubmed.ncbi.nlm.nih.gov/30665573/ Proteinuria Medication https://emedicine.medscape.com/article/238158-medication Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK576405/ Dapagliflozin in Patients With Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/32970396/ Empagliflozin in Patients With Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/36331190/ Long-Term Follow-Up of Cyclical Cyclophosphamide and Steroids Versus Tacrolimus and Steroids in Primary Membranous Nephropathy https://pubmed.ncbi.nlm.nih.gov/34622104/ Strategies Towards Antigen-Specific Treatments for Membranous Nephropathy https://pubmed.ncbi.nlm.nih.gov/35185913/ Transplant Candidate https://kdigo.org/guidelines/transplant-candidate/
Endocrine Review Course Episode 11 Learning Objectives: Describe screening for diabetic nephropathy in patients with type 1 and type 2 diabetes Identify patients who do not fit the typical diabetic nephropathy phenotype and refer them for further testing List the management strategies for patients with diabetic nephropathy
Experts Drs Matthew A. Sparks and Dana V. Rizk discuss the pathology, presentation, and management of IgA nephropathy. Looking for the latest on clinical trials and approved treatments? Tune in! Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/991603). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Chronic Kidney Disease (CKD) https://emedicine.medscape.com/article/238798-overview IgA Nephropathy https://emedicine.medscape.com/article/239927-overview Polycystic Kidney Disease https://emedicine.medscape.com/article/244907-overview Biomarkers for IgA Nephropathy on the Basis of Multi-Hit Pathogenesis https://pubmed.ncbi.nlm.nih.gov/29740706/ Galactose-Deficient IgA1 as a Candidate Urinary Marker of IgA Nephropathy https://pubmed.ncbi.nlm.nih.gov/35683557/ Immunological Drivers of IgA Nephropathy: Exploring the Mucosa-Kidney Link https://pubmed.ncbi.nlm.nih.gov/34821031/ Nephrotic Syndrome https://emedicine.medscape.com/article/244631-overview Podocytopathies https://pubmed.ncbi.nlm.nih.gov/32792490/ Minimal-Change Disease https://emedicine.medscape.com/article/243348-overview IgA Vasculitis (Henoch-Schönlein Purpura) https://emedicine.medscape.com/article/984105-overview Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK576405/ Dapagliflozin in Patients With Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/32970396/ Empagliflozin in Patients With Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/36331190/ A Controlled Trial of Fish Oil in IgA Nephropathy. Mayo Nephrology Collaborative Group https://pubmed.ncbi.nlm.nih.gov/7935657/ Fish Consumption, Omega 3 Fatty Acids and Cardiovascular Disease. The Science and the Clinical Trials https://pubmed.ncbi.nlm.nih.gov/19326716/ Tonsillectomy in a European Cohort of 1,147 Patients With IgA Nephropathy https://pubmed.ncbi.nlm.nih.gov/26586175/ Sparsentan in Patients With IgA Nephropathy: A Prespecified Interim Analysis From a Randomised, Double-Blind, Active-Controlled Clinical Trial https://pubmed.ncbi.nlm.nih.gov/37015244/ Intensive Supportive Care Plus Immunosuppression in IgA Nephropathy https://pubmed.ncbi.nlm.nih.gov/26962737/ Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/28763548/ Targeted-Release Budesonide Versus Placebo in Patients With IgA Nephropathy (NEFIGAN): A Double-Blind, Randomised, Placebo-Controlled Phase 2b Trial https://pubmed.ncbi.nlm.nih.gov/28363480/ Results From Part A of the Multi-Center, Double-Blind, Randomized, Placebo-Controlled NefIgArd Trial, Which Evaluated Targeted-Release Formulation of Budesonide for the Treatment of Primary Immunoglobulin A Nephropathy https://pubmed.ncbi.nlm.nih.gov/36270561/ Crescents and IgA Nephropathy: A Delicate Marriage https://pubmed.ncbi.nlm.nih.gov/35806856/ Crescentic, Proliferative IgA Nephropathy: Clinical and Histological Response to Methylprednisolone and Intravenous Cyclophosphamide https://pubmed.ncbi.nlm.nih.gov/12808169/ Hydroxychloroquine Inhibits Macrophage Activation and Attenuates Renal Fibrosis After Ischemia-Reperfusion Injury https://pubmed.ncbi.nlm.nih.gov/33936063/ New Treatment Strategies for IgA Nephropathy: Targeting Plasma Cells as the Main Source of Pathogenic Antibodies https://pubmed.ncbi.nlm.nih.gov/35628935/
Did you know that immunoglobulin A nephropathy has very recently seen 2 treatments first licensed for its management? Credit available for this activity expires: 6/29/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/993766?ecd=bdc_podcast_libsyn_mscpedu
A macrovascular complication of diabetes, diabetic nephropathy is progressive, chronic kidney disease seen in patients with both type 1 and type 2 diabetes mellitus, usually after at least 10 years of hyperglycemia (high blood glucose levels). The three main lesions that are seen in the kidney in patients with diabetes are glomerular lesions, vascular lesions, and pyelonephritis. This brick will focus primarily on the first two of these three lesions; diabetic pyelonephritis is covered in a separate brick. After listening to this AudioBrick, you should be able to: Define diabetic nephropathy. Outline the timeline of progression of diabetic nephropathy (DN) by urine, serum, and histologic criteria. Describe the diagnosis of diabetic nephropathy. Outline the prevention of diabetic nephropathy and, once it is established, how to slow its progression. Describe the management of diabetic nephropathy. You can also check out the original brick from our Renal collection, which is available for free. Learn more about Rx Bricks by signing up for a free USMLE-Rx account: www.usmle-rx.com You will get 5 days of full access to our Rx360+ program, including nearly 800 Rx Bricks. After the 5-day period, you will still be able to access over 150 free bricks, including the entire collections for General Microbiology and Cellular and Molecular Biology. *** If you enjoyed this episode, we'd love for you to leave a review on Apple Podcasts. It helps with our visibility, and the more med students (or future med students) listen to the podcast, the more we can provide to the future physicians of the world. Follow USMLE-Rx at: Facebook: www.facebook.com/usmlerx Blog: www.firstaidteam.com Twitter: https://twitter.com/firstaidteam Instagram: https://www.instagram.com/firstaidteam/ YouTube: www.youtube.com/USMLERX Learn how you can access over 150 of our bricks for FREE: https://usmlerx.wpengine.com/free-bricks/
The kidney is one of the organs necessary to filter blood, composed of tiny functional units that separate waste products from molecules the body should retain. Chronic kidney disease is a significant international problem, with up to 10% of the population requiring treatment, and extreme cases requiring dialysis and/or transplantation with significant personal and public health costs. In today's episode we speak with Dr. Andrew King, Chief Scientific Officer of Chinook Therapeutics. We discuss rare diseases of the kidney, such as disorders that lead to nephropathy, proteinuria, and oxalic acid deposition, along with how the next generation of drugs work to target these issues. www.chinooktx.com
To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/igan-ee-podcastThis activity will take learners on a deep dive into the pathophysiology of proteinuric glomerular disease, with an incisive focus on IgA nephropathy (IgAN). Expert faculty will review the totality of emerging evidence for novel therapeutics in IgAN, including an appraisal of consensus guidelines and regulatory updates. Finally, the session will conclude with a case-based segment wherein attendees will get to apply the principles they've learned to real-world clinical scenarios.Supported through an independent educational grant from Travere.
Beyond the Pearls: Cases for Med School, Residency and Beyond (An InsideTheBoards Podcast)
Today's Episode Dr. Raj reviews diabetic nephropathy which is the leading cause of leading cause of end-stage kidney disease. He reviews the causes and treatment options and breaks down a practice question to bring everything together. Enter the 100th Episode Giveaway The contest is running from March 1st, 2023 to April 14th, 2023 and winners will be announced on April 17th, 2023. 6 winners will be chosen from the entries and all you have to do is enter your email address to be entered. We will reach out to the winners after the contest to send them their copy of the book. Please visit the link to see all rules and details and to enter the contest. Link to the giveaway! About Dr. Raj Dr Raj is a quadruple board certified physician and associate professor at the University of Southern California. He was a co-host on the TNT series Chasing the Cure with Ann Curry, a regular on the TV Show The Doctors for the past 7 seasons and has a weekly medical segment on ABC news Los Angeles. More from Dr. Raj www.BeyondThePearls.net The Dr. Raj Podcast Dr. Raj on Twitter Dr. Raj on Instagram Want more board review content? Physiology by Physeo Step 1 Success Stories The InsideTheBoards Study Smarter Podcast The InsideTheBoards Podcast Study on the go for free! Download the Audio QBank by InsideTheBoards for free on iOS or Android. If you want to upgrade, you can save money on a premium subscription by customizing your plan until your test date on our website! Produced by Ars Longa Media To learn more about us and this podcast, visit arslonga.media. You can leave feedback or suggestions at arslonga.media/contact or by emailing info@arslonga.media. Produced by: Christopher Breitigan Executive Producer: Patrick C. Beeman, MD Legal Stuff InsideTheBoards is not affiliated with the NBME, USMLE, COMLEX, or any professional licensing body. InsideTheBoards and its partners fully adhere to the policies on irregular conduct outlined by the aforementioned credentialing bodies. The information presented in this podcast is intended for educational purposes only and should not be construed as professional or medical advice. Learn more about your ad choices. Visit megaphone.fm/adchoices
In this episode, we review the high-yield topic of Sickle Cell Nephropathy from the Renal section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets --- Send in a voice message: https://anchor.fm/medbulletsstep1/message
Looking for more information on this topic? Check out the IgA Nephropathy and Henoch-Schönlein Purpura brick. If you enjoyed this episode, we'd love for you to leave a review on Apple Podcasts. It helps with our visibility, and the more med students (or future med students) listen to the podcast, the more we can provide to the future physicians of the world. Follow USMLE-Rx at: Facebook: www.facebook.com/usmlerx Blog: www.firstaidteam.com Twitter: https://twitter.com/firstaidteam Twitter: https://twitter.com/mesage_hub Instagram: https://www.instagram.com/firstaidteam/ YouTube: www.youtube.com/USMLERX Learn more about Rx Bricks by signing up for a free USMLE-Rx account: www.usmle-rx.com You will get 5 days of full access to our Rx360+ program, including over 800 Rx Bricks. After the 5-day period, you will still be able to access over 150 free bricks, including the entire collections for General Microbiology and Cellular and Molecular Biology.
SGLT2 inhibitors, publishing choices, second and third order effects of interventions, decision support, and patient selection for preventive procedures are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. EMPA Kidney - EMPA-Kidney Seals SGLT2 Inhibitors as 'Foundational' for CKD https://www.medscape.com/viewarticle/984439 - EMPA-Kidney Moves the Needle for SGLT2 Inhibitors in Kidney Disease https://www.medscape.com/viewarticle/983521 - Empagliflozin in Patients with Chronic Kidney Disease https://www.nejm.org/doi/pdf/10.1056/NEJMoa2204233 - Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy https://www.nejm.org/doi/10.1056/NEJMoa1811744 - Dapagliflozin in Patients with Chronic Kidney Disease https://www.nejm.org/doi/full/10.1056/NEJMoa2024816 - Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials https://doi.org/10.1016/S0140-6736(22)02074-8 II. Publishing Choices - Motorcycle Rallies Linked to Spike in Organ Transplants https://www.medscape.com/viewarticle/984623 - Organ Donation and Transplants During Major US Motorcycle Rallies https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2798550 III. Second and Third Order Effects - Heart Disease Deaths Spiked During COVID After 10-Year Decline https://www.medscape.com/viewarticle/984605 IV. Decision Support - Patient App Aids Decisions on Anticoagulants: ENHANCE-AF https://www.medscape.com/viewarticle/984253 - A Randomized Clinical Trial to Evaluate an Atrial Fibrillation Stroke Prevention Shared Decision‐Making Pathway https://www.ahajournals.org/doi/10.1161/JAHA.122.028562 V. Percutaneous Left Atrial Appendage Closure - Consider Life Expectancy When Referring for LAA Closure? https://www.medscape.com/viewarticle/981117 - Transcatheter Left Atrial Appendage Occlusion: A Multi-Center Real Life Experience https://www.mdpi.com/2077-0383/11/23/6944 - Incidence and Predictors of Early Death in Patients Undergoing Percutaneous Left Atrial Appendage Closure https://www.jacc.org/doi/full/10.1016/j.jacep.2022.06.012 - Indications for Left Atrial Appendage Occlusion in the United States and Associated In-Hospital Outcomes: Results From the NCDR LAAO Registry https://www.ahajournals.org/doi/full/10.1161/CIRCOUTCOMES.121.008418 You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net